To isolate the DNA fragment containing the FFL coding region, the sequence GGATCT (nt. 1891/1896) at the 3′ flanking region of FFL cDNA in pGL2-basic vector (Promega, Madison, WI, U.S.A.) was mutated to the BamHI site (GGATCC) using a site-directed mutagenesis kit (Stratagene, La Jolla, CA, U.S.A.). This mutant plasmid was digested with HindIII and BamHI, and the 1750 bp DNA fragment was separated in gel electrophoresis and was ligated in the HindIII-BamHI site in the multi-cloning site in pBL-CAT5 [24] (link) (Fig. 1A ). Using the site-directed mutagenesis kit (Stratagene, U.S.A.), the positive TRE (pTRE)-like sequence (AGGTGA-CGCG-TGTGGCC) in the thymidine kinase (TK) promoter [25] (link) of pBL-FFL-CAT5 was mutated to generate pBL-FFL-CAT5-mtk. Deletion mutants of pBL-FFL-CAT5 were generated using PCR and standard molecular biology techniques. The sequence between nt. 626/640 in FFL cDNA was mutated using the site-directed mutagenesis kit to generate the constructs, MA, MB, MC, and MD. The coding regions for hRluc and Luc2 were excised with HindIII and XbaI from phRL-null vector and pGL4.10 [luc2] vector (Promega), respectively. These DNA fragments were subcloned into the HindIII-XbaI sequence of pBL-CAT5 to create pBL-hRluc-CAT5 and pBL-Luc2-CAT5. All plasmid constructs were confirmed by sequencing. The expression plasmids for human TRβ1 (pCMX-hTRβ1), estrogen receptor α (pSG5-hERα), vitamin D3 receptor (pSG5-hVDR), retinoic acid receptor (RAR) α (pCMX-hRARα), and glucocorticoid receptor (GR) (pCMX-hGR) were as described previously [26] (link), [27] (link).
Full text: Click here